Mohammad Khalafi, MD

599 posts

Mohammad Khalafi, MD banner
Mohammad Khalafi, MD

Mohammad Khalafi, MD

@klf_mohammad

Postdoc Researcher @WCMRadiology, Brain Health Imaging Institute (BHII) || Associate Editor (TEB) @Radiology_RSNA

New York, NY Katılım Mayıs 2022
982 Takip Edilen402 Takipçiler
Mohammad Khalafi, MD retweetledi
AJNR
AJNR@TheAJNR·
We are pleased to acknowledge the help of the following individuals in reviewing manuscripts for the year 2025. These individuals are not part of our Editorial Board. They reviewed the largest number of manuscripts and received the highest scores for their work. Without their efforts, the quality of AJNR would not be what it is. The Editors thank them profoundly and hope they will keep up their good work and perhaps even join us as members of the Editorial Board in the future. ajnr.org/page/content/R… Interested in becoming an AJNR reviewer? Visit the Academy of Reviewers for tips and guidelines. ajnr.org/content/academ…
AJNR tweet media
English
1
7
20
878
Mohammad Khalafi, MD
Mohammad Khalafi, MD@klf_mohammad·
8/8 CT radiomics approach helps uncover hidden tumor biology in HCC and moves us toward more personalized care! Future studies should focus on larger prospective validation and integration into clinical workflows!   Read more📄➡️: pubs.rsna.org/doi/10.1148/ra…
English
0
0
1
28
Mohammad Khalafi, MD
Mohammad Khalafi, MD@klf_mohammad·
7/8 Rad-ITF score offers a noninvasive way to grade intratumoral fibrosis, stratify prognosis after TACE, and serve as a surrogate marker for tumor angiogenesis in HCC. It helps identify patients who could benefit from combined TACE and anti-angiogenic therapy.  #RadInTraining
Mohammad Khalafi, MD tweet media
English
1
0
1
37
Mohammad Khalafi, MD retweetledi
@RadiologyEditor
@RadiologyEditor@RadiologyEditor·
Your MRI might be telling you more than you think🧲 Muscle is a biomarker 💪 In 11,348 adults, MRI + deep learning showed: ↑ intermuscular fat (IMAT) = higher cardiometabolic risk, while more lean muscle = more protection (esp. in men) Worth a read 👇 pubs.rsna.org/doi/10.1148/ra…
@RadiologyEditor tweet media
English
1
1
5
265
Mohammad Khalafi, MD retweetledi
Amirhossein Roshanshad, MD
Amirhossein Roshanshad, MD@ARoshanshad·
1/13 🎯 MASLD is the most common chronic liver disease. FDA just approved drugs for fibrotic MASH. To monitor treatment response, we need precise liver stiffness measurements. Do we have the right tool for patients with obesity?
English
1
2
13
755